Check-Cap Ltd. (NASDAQ:CHEK) has revealed on Monday that it has entered into a $5.90-million registered direct offering agreement with an institutional investor. Subject to regulatory requirements, the deal is expected to close on Thursday.

Terms of the Agreement

The agreement involves a total of 643,614 ordinary shares worth $1.90 each and 2.50 million pre-funded warrants worth $1.85 each. Once all warrants have been exercised, Check-Cap will generate a total of $6 million in gross proceeds.

The net proceeds from the deal will be used primarily for the ongoing clinical development of the company’s colorectal cancer screening platform and other corporate expenses.

For this agreement, Chardan Capital Markets LLC served as the exclusive placement agent while Roth Capital Partners and Maxim Group LLC both served as financial advisors.

Check-Cap’s Partnership with GE Healthcare Ltd.

Last week, Check-Cap confirmed that it had also struck a collaboration agreement with GE Healthcare for the development of X-ray source production and assembly and evaluate high-volume manufacturing into the former’s capsule.

Bill Densel, Check-Cap CEO, expressed in behalf of the company that he is excited to work with GE Healthcare as part of its efforts to improve its offerings. As a global leader in the pharmaceutical and biotechnology industry, Densel believes that GE Healthcare will help Check-Cap to further explore potential developments and innovations, especially when it comes to colorectal cancer.

Check-Cap on Colorectal Cancer

Presently, colorectal cancer is one of the leading cancer-related deaths in the US. So far this year, there are already 49,000 deaths caused by and/or associated with colorectal cancer.

In its attempts to develop safe and effective treatments and improve the lives of colorectal cancer patients, Check-Cap is working on a multicenter clinical feasibility study.

Recently, the company has received a grant of about $1.25 million from the Office of the Chief Scientist (OCS) in Israel. Check-Cap intends to use the funding primarily for the ongoing clinical development of its capsule technology.

The OCS aims to support the innovative research and development (R&D) efforts and initiatives in Israel, believing that it is a way of facilitating and boosting economic growth.

Previous articleUS FDA Approves Amarin Corporation plc (NASDAQ:AMRN) SPA Agreement Amendment For REDUCE-IT; Amarin Reports Q2 Financial Results
Next articleBTCS Inc (OTCMKTS:BTCS) Expands Its Ethereum-Mining Hosting Operations
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.